Pharvaris (PHVS)
NASDAQ:PHVS
Top Page
Pharvaris
(NASDAQ:PHVS)
Select Model
Select Model
Rating:57Neutral
Price Target:
$30.00
▲(7.76% Upside)
Action:ReiteratedDate:04/06/26
The score is primarily held back by weak financial performance driven by ongoing losses and increasing cash burn, despite a conservatively levered balance sheet. Technicals are supportive with the stock trading above major moving averages and positive momentum, while valuation remains challenged due to a negative P/E and no dividend yield provided.
Positive Factors
Pivotal Phase 3 success
A positive pivotal RAPIDe-3 readout materially de-risks regulatory submission and underpins an imminent NDA for an on‑demand HAE therapy. Over 2–6 months this shifts Pharvaris from pure development to regulatory execution, increasing the probability of approval and future revenue opportunities.
Negative Factors
Pre‑revenue with widening losses
Pharvaris remains pre‑commercial and posted materially higher net losses in 2025, reflecting sustained R&D investment. Over the medium term this elevates reliance on external financing and heightens dilution risk if approvals or commercial inflection points are delayed or require additional spend.
Read all positive and negative factors
Positive Factors
Negative Factors
Pivotal Phase 3 success
A positive pivotal RAPIDe-3 readout materially de-risks regulatory submission and underpins an imminent NDA for an on‑demand HAE therapy. Over 2–6 months this shifts Pharvaris from pure development to regulatory execution, increasing the probability of approval and future revenue opportunities.
Read all positive factors
Pharvaris (PHVS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.77B
Dividend YieldN/A
Average Volume (3M)174.44K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue GrowthN/A
EPS Growth-20.08%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.84
Shares Outstanding64,055,640
10 Day Avg. Volume252,435
30 Day Avg. Volume174,443
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.51
Forecast
1Y Price Target
$44.80Price Target Upside60.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.96
Revenue Forecast (FY)N/A
Pharvaris Business Overview & Revenue Model
Company Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinic...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Pharvaris does not have a stable, ongoing product-revenue stream from marketed drugs (null). Its cash inflows are primarily generated through financing activities rather than operations, including: (1...
Pharvaris Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -169.40M | -145.59M | -96.66M | -86.56M | -54.06M |
| Net Income | -175.70M | -134.22M | -100.88M | -76.33M | -42.73M |
Balance Sheet | |||||
| Total Assets | 301.45M | 291.37M | 398.69M | 167.73M | 212.09M |
| Cash, Cash Equivalents and Short-Term Investments | 291.68M | 280.73M | 391.23M | 161.84M | 209.35M |
| Total Debt | 776.80K | 861.47K | 238.91K | 436.82K | 250.18K |
| Total Liabilities | 30.18M | 23.61M | 14.65M | 18.47M | 7.14M |
| Stockholders Equity | 271.27M | 267.76M | 384.05M | 149.26M | 204.95M |
Cash Flow | |||||
| Free Cash Flow | -137.24M | -120.67M | -93.14M | -67.29M | -44.73M |
| Operating Cash Flow | -137.07M | -120.13M | -93.05M | -67.16M | -44.60M |
| Investing Cash Flow | -164.62K | -538.09K | -89.98K | -124.30K | -130.03K |
| Financing Cash Flow | 160.61M | 2.68M | 325.39M | 8.65M | 143.67M |
Pharvaris Technical Analysis
Positive
27.84
Price Trends
27.08
Positive
26.35
Positive
24.18
Positive
Market Momentum
0.38
Negative
52.16
Neutral
54.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Positive. The current price of 27.84 is above the 20-day moving average (MA) of 27.03, above the 50-day MA of 27.08, and above the 200-day MA of 24.18, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 54.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHVS.
Pharvaris Risk Analysis
Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our articles of association designate specific courts as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Q4, 2023
2.
to successfully commercialize our product candidates, or experience significant delays in doing so, our business, financial condition, results of operations and prospects would be materially adversely affected. Q4, 2023
Pharvaris Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $2.45B | 6.20 | -76.45% | ― | 45.38% | 92.85% | |
61 Neutral | $3.54B | -12.72 | -31.97% | ― | ― | -5.73% | |
57 Neutral | $1.77B | -7.95 | -70.76% | ― | ― | -20.08% | |
56 Neutral | $2.16B | ― | -41.68% | ― | -73.94% | -31.70% | |
54 Neutral | $1.48B | -5.48 | -58.44% | ― | 23340.07% | 18.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $1.41B | -1.64 | -688.89% | ― | ― | 18.76% |
* Healthcare Sector Average
PHVS
Pharvaris
27.56
15.26
124.07%
BCRX
BioCryst
9.78
3.01
44.46%
CLDX
Celldex
32.41
16.00
97.50%
VRDN
Viridian Therapeutics
14.47
2.68
22.73%
EWTX
Edgewise Therapeutics
33.04
20.54
164.32%
BHVN
Biohaven Ltd.
9.38
-9.29
-49.76%
Pharvaris Corporate Events
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
Apr 2, 2026
On April 2, 2026, Pharvaris reported fourth-quarter and full-year 2025 results that underline its transition toward late-stage commercialization in rare angioedema disorders. The company closed 2025 with €291.7 million in cash and cash equiv...
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
Jan 12, 2026
On January 12, 2026, Pharvaris outlined its 2026 strategic priorities centered on advancing deucrictibant through late-stage development and toward commercialization in hereditary and acquired angioedema. Following the December readout of its pivo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.